English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18074/20272 (89%)
造訪人次 : 4289472      線上人數 : 5466
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/32542


    標題: Over-Expression of CHD4 Is an Independent Biomarker of Poor Prognosis in Patients with Rectal Cancers Receiving Concurrent Chemoradiotherapy
    作者: Wang, Hui-Ching
    Chou, Chia-Lin
    Ching-Chieh Yang(楊清傑)
    Huang, Wei-Lun
    Hsu, Yin-Chou
    Luo, Chi-Wen
    Chen, Tzu-Ju
    Li, Chien-Feng
    Pan, Mei-Ren
    貢獻者: Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med
    Kaohsiung Med Univ, Div Hematol & Oncol, Dept Internal Med, Kaohsiung Med Univ Hosp
    Chi Mei Med Ctr, Div Colon & Rectal Surg, Dept Surg
    Natl Sun Yat Sen Univ, Inst Biomed Sci
    Chi Mei Med Ctr, Dept Radiat Oncol
    Chia Nan Univ Pharm & Sci, Dept Pharm
    Kaohsiung Vet Gen Hosp, Dept Radiat Oncol
    I Shou Univ, Dept Emergency Med, E Da Hosp
    Kaohsiung Med Univ Hosp, Div Breast Surg, Dept Surg
    Chi Mei Med Ctr, Dept Pathol
    Chung Hwa Univ Med Technol, Dept Optometry
    Chi Mei Med Ctr, Dept Med Res
    Natl Hlth Res Inst, Natl Inst Canc Res
    Kaohsiung Med Univ, Drug Dev & Value Creat Res Ctr
    關鍵字: CHD4
    CCRT
    rectal cancers
    radioresistance
    日期: 2019-09
    上傳時間: 2020-07-29 13:49:10 (UTC+8)
    出版者: MDPI
    摘要: Neoadjuvant concurrent chemoradiotherapy (CCRT), followed by radical proctectomy, is the standard treatment for locally advanced rectal cancer. However, a poor response and therapeutic resistance continue to occur despite this treatment. In this study, we analyzed the microarray datasets (GSE68204) of rectal cancer from the Gene Expression Omnibus database, and identified CHD4 as one of the most significantly up-regulated genes among all subunits of the nucleosome remodeling and histone deacetylation (NuRD) complex, in non-responders to CCRT, among locally advanced rectal cancer (LARC) patients. We confirmed the predictive and prognostic significance of CHD4 expression in CCRT treatment, and its correlation with other clinicopathological features, such as tumor regression grade (TRG), therapeutic response, and patient survival. This was carried out by immunohistochemical studies on endoscopic biopsy tissues from 172 rectal cancer patients, receiving neoadjuvant concurrent chemoradiotherapy (CCRT). A high expression of CHD4 was significantly associated with pre-treatment tumor status (p < 0.001) and lymph node metastasis (p < 0.001), post-treatment tumor status (p < 0.001), and lymph node metastasis (p < 0.001), vascular invasion (p = 0.042), and tumor regression grade (p = 0.001). A high expression of CHD4 could also predict poor disease-specific survival and metastasis-free survival (log-rank test, p = 0.0373 and p < 0.0001, respectively). In multivariate Cox proportional-hazards regression analysis, CHD4 overexpression was an independent factor of poor prognosis for metastasis-free survival (HR, 4.575; 95% CI, 1.717-12.192; p = 0.002). By in vitro studies, based on cell line models, we also demonstrated that, the overexpression of CHD4 induced radio-resistance in microsatellite instability-high (MSI-H) colorectal cells (CRCs). On the contrary, the knockdown of CHD4 enhanced radiosensitivity in microsatellite stable (MSS) CRCs. Altogether, we have identified CHD4 as an important regulator of radio-resistance in both MSI-H and MSS CRC cell lines.
    關聯: International Journal of Molecular Sciences, v.20, n.17, 4087
    顯示於類別:[藥學系(所)] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    10.3390-ijms20174087.pdf1493KbAdobe PDF306檢視/開啟
    index.html0KbHTML1360檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋